Copyright Reports & Markets. All rights reserved.

Global Metabotropic Glutamate Antagonists Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope of Metabotropic Glutamate Antagonists
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Metabotropic Glutamate Antagonists Consumption Value by Type: 2018 Versus 2022 Versus 2029
    • 1.3.2 Ionic
    • 1.3.3 Non Ionic
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global Metabotropic Glutamate Antagonists Consumption Value by Application: 2018 Versus 2022 Versus 2029
    • 1.4.2 Hospitals And Clinics
    • 1.4.3 Research Institutes
    • 1.4.4 Others
  • 1.5 Global Metabotropic Glutamate Antagonists Market Size & Forecast
    • 1.5.1 Global Metabotropic Glutamate Antagonists Consumption Value (2018 & 2022 & 2029)
    • 1.5.2 Global Metabotropic Glutamate Antagonists Sales Quantity (2018-2029)
    • 1.5.3 Global Metabotropic Glutamate Antagonists Average Price (2018-2029)

2 Manufacturers Profiles

  • 2.1 Artemis Neuroscience
    • 2.1.1 Artemis Neuroscience Details
    • 2.1.2 Artemis Neuroscience Major Business
    • 2.1.3 Artemis Neuroscience Metabotropic Glutamate Antagonists Product and Services
    • 2.1.4 Artemis Neuroscience Metabotropic Glutamate Antagonists Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.1.5 Artemis Neuroscience Recent Developments/Updates
  • 2.2 VistaGen Therapeutics
    • 2.2.1 VistaGen Therapeutics Details
    • 2.2.2 VistaGen Therapeutics Major Business
    • 2.2.3 VistaGen Therapeutics Metabotropic Glutamate Antagonists Product and Services
    • 2.2.4 VistaGen Therapeutics Metabotropic Glutamate Antagonists Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.2.5 VistaGen Therapeutics Recent Developments/Updates
  • 2.3 Rottapharm Madaus
    • 2.3.1 Rottapharm Madaus Details
    • 2.3.2 Rottapharm Madaus Major Business
    • 2.3.3 Rottapharm Madaus Metabotropic Glutamate Antagonists Product and Services
    • 2.3.4 Rottapharm Madaus Metabotropic Glutamate Antagonists Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.3.5 Rottapharm Madaus Recent Developments/Updates
  • 2.4 Amorsa Therapeutics
    • 2.4.1 Amorsa Therapeutics Details
    • 2.4.2 Amorsa Therapeutics Major Business
    • 2.4.3 Amorsa Therapeutics Metabotropic Glutamate Antagonists Product and Services
    • 2.4.4 Amorsa Therapeutics Metabotropic Glutamate Antagonists Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.4.5 Amorsa Therapeutics Recent Developments/Updates
  • 2.5 Newron Pharmaceuticals
    • 2.5.1 Newron Pharmaceuticals Details
    • 2.5.2 Newron Pharmaceuticals Major Business
    • 2.5.3 Newron Pharmaceuticals Metabotropic Glutamate Antagonists Product and Services
    • 2.5.4 Newron Pharmaceuticals Metabotropic Glutamate Antagonists Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.5.5 Newron Pharmaceuticals Recent Developments/Updates
  • 2.6 Purdue Biopharma
    • 2.6.1 Purdue Biopharma Details
    • 2.6.2 Purdue Biopharma Major Business
    • 2.6.3 Purdue Biopharma Metabotropic Glutamate Antagonists Product and Services
    • 2.6.4 Purdue Biopharma Metabotropic Glutamate Antagonists Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.6.5 Purdue Biopharma Recent Developments/Updates
  • 2.7 Relmada Therapeutics
    • 2.7.1 Relmada Therapeutics Details
    • 2.7.2 Relmada Therapeutics Major Business
    • 2.7.3 Relmada Therapeutics Metabotropic Glutamate Antagonists Product and Services
    • 2.7.4 Relmada Therapeutics Metabotropic Glutamate Antagonists Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.7.5 Relmada Therapeutics Recent Developments/Updates
  • 2.8 BioCrea GmbH
    • 2.8.1 BioCrea GmbH Details
    • 2.8.2 BioCrea GmbH Major Business
    • 2.8.3 BioCrea GmbH Metabotropic Glutamate Antagonists Product and Services
    • 2.8.4 BioCrea GmbH Metabotropic Glutamate Antagonists Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.8.5 BioCrea GmbH Recent Developments/Updates
  • 2.9 Cerecor Inc.
    • 2.9.1 Cerecor Inc. Details
    • 2.9.2 Cerecor Inc. Major Business
    • 2.9.3 Cerecor Inc. Metabotropic Glutamate Antagonists Product and Services
    • 2.9.4 Cerecor Inc. Metabotropic Glutamate Antagonists Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.9.5 Cerecor Inc. Recent Developments/Updates
  • 2.10 NeurOp Inc.
    • 2.10.1 NeurOp Inc. Details
    • 2.10.2 NeurOp Inc. Major Business
    • 2.10.3 NeurOp Inc. Metabotropic Glutamate Antagonists Product and Services
    • 2.10.4 NeurOp Inc. Metabotropic Glutamate Antagonists Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.10.5 NeurOp Inc. Recent Developments/Updates
  • 2.11 UCB SA
    • 2.11.1 UCB SA Details
    • 2.11.2 UCB SA Major Business
    • 2.11.3 UCB SA Metabotropic Glutamate Antagonists Product and Services
    • 2.11.4 UCB SA Metabotropic Glutamate Antagonists Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.11.5 UCB SA Recent Developments/Updates
  • 2.12 Novartis AG
    • 2.12.1 Novartis AG Details
    • 2.12.2 Novartis AG Major Business
    • 2.12.3 Novartis AG Metabotropic Glutamate Antagonists Product and Services
    • 2.12.4 Novartis AG Metabotropic Glutamate Antagonists Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.12.5 Novartis AG Recent Developments/Updates
  • 2.13 Luc Therapeutics Inc.
    • 2.13.1 Luc Therapeutics Inc. Details
    • 2.13.2 Luc Therapeutics Inc. Major Business
    • 2.13.3 Luc Therapeutics Inc. Metabotropic Glutamate Antagonists Product and Services
    • 2.13.4 Luc Therapeutics Inc. Metabotropic Glutamate Antagonists Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.13.5 Luc Therapeutics Inc. Recent Developments/Updates
  • 2.14 Evotec AG
    • 2.14.1 Evotec AG Details
    • 2.14.2 Evotec AG Major Business
    • 2.14.3 Evotec AG Metabotropic Glutamate Antagonists Product and Services
    • 2.14.4 Evotec AG Metabotropic Glutamate Antagonists Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.14.5 Evotec AG Recent Developments/Updates

3 Competitive Environment: Metabotropic Glutamate Antagonists by Manufacturer

  • 3.1 Global Metabotropic Glutamate Antagonists Sales Quantity by Manufacturer (2018-2023)
  • 3.2 Global Metabotropic Glutamate Antagonists Revenue by Manufacturer (2018-2023)
  • 3.3 Global Metabotropic Glutamate Antagonists Average Price by Manufacturer (2018-2023)
  • 3.4 Market Share Analysis (2022)
    • 3.4.1 Producer Shipments of Metabotropic Glutamate Antagonists by Manufacturer Revenue ($MM) and Market Share (%): 2022
    • 3.4.2 Top 3 Metabotropic Glutamate Antagonists Manufacturer Market Share in 2022
    • 3.4.2 Top 6 Metabotropic Glutamate Antagonists Manufacturer Market Share in 2022
  • 3.5 Metabotropic Glutamate Antagonists Market: Overall Company Footprint Analysis
    • 3.5.1 Metabotropic Glutamate Antagonists Market: Region Footprint
    • 3.5.2 Metabotropic Glutamate Antagonists Market: Company Product Type Footprint
    • 3.5.3 Metabotropic Glutamate Antagonists Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Metabotropic Glutamate Antagonists Market Size by Region
    • 4.1.1 Global Metabotropic Glutamate Antagonists Sales Quantity by Region (2018-2029)
    • 4.1.2 Global Metabotropic Glutamate Antagonists Consumption Value by Region (2018-2029)
    • 4.1.3 Global Metabotropic Glutamate Antagonists Average Price by Region (2018-2029)
  • 4.2 North America Metabotropic Glutamate Antagonists Consumption Value (2018-2029)
  • 4.3 Europe Metabotropic Glutamate Antagonists Consumption Value (2018-2029)
  • 4.4 Asia-Pacific Metabotropic Glutamate Antagonists Consumption Value (2018-2029)
  • 4.5 South America Metabotropic Glutamate Antagonists Consumption Value (2018-2029)
  • 4.6 Middle East and Africa Metabotropic Glutamate Antagonists Consumption Value (2018-2029)

5 Market Segment by Type

  • 5.1 Global Metabotropic Glutamate Antagonists Sales Quantity by Type (2018-2029)
  • 5.2 Global Metabotropic Glutamate Antagonists Consumption Value by Type (2018-2029)
  • 5.3 Global Metabotropic Glutamate Antagonists Average Price by Type (2018-2029)

6 Market Segment by Application

  • 6.1 Global Metabotropic Glutamate Antagonists Sales Quantity by Application (2018-2029)
  • 6.2 Global Metabotropic Glutamate Antagonists Consumption Value by Application (2018-2029)
  • 6.3 Global Metabotropic Glutamate Antagonists Average Price by Application (2018-2029)

7 North America

  • 7.1 North America Metabotropic Glutamate Antagonists Sales Quantity by Type (2018-2029)
  • 7.2 North America Metabotropic Glutamate Antagonists Sales Quantity by Application (2018-2029)
  • 7.3 North America Metabotropic Glutamate Antagonists Market Size by Country
    • 7.3.1 North America Metabotropic Glutamate Antagonists Sales Quantity by Country (2018-2029)
    • 7.3.2 North America Metabotropic Glutamate Antagonists Consumption Value by Country (2018-2029)
    • 7.3.3 United States Market Size and Forecast (2018-2029)
    • 7.3.4 Canada Market Size and Forecast (2018-2029)
    • 7.3.5 Mexico Market Size and Forecast (2018-2029)

8 Europe

  • 8.1 Europe Metabotropic Glutamate Antagonists Sales Quantity by Type (2018-2029)
  • 8.2 Europe Metabotropic Glutamate Antagonists Sales Quantity by Application (2018-2029)
  • 8.3 Europe Metabotropic Glutamate Antagonists Market Size by Country
    • 8.3.1 Europe Metabotropic Glutamate Antagonists Sales Quantity by Country (2018-2029)
    • 8.3.2 Europe Metabotropic Glutamate Antagonists Consumption Value by Country (2018-2029)
    • 8.3.3 Germany Market Size and Forecast (2018-2029)
    • 8.3.4 France Market Size and Forecast (2018-2029)
    • 8.3.5 United Kingdom Market Size and Forecast (2018-2029)
    • 8.3.6 Russia Market Size and Forecast (2018-2029)
    • 8.3.7 Italy Market Size and Forecast (2018-2029)

9 Asia-Pacific

  • 9.1 Asia-Pacific Metabotropic Glutamate Antagonists Sales Quantity by Type (2018-2029)
  • 9.2 Asia-Pacific Metabotropic Glutamate Antagonists Sales Quantity by Application (2018-2029)
  • 9.3 Asia-Pacific Metabotropic Glutamate Antagonists Market Size by Region
    • 9.3.1 Asia-Pacific Metabotropic Glutamate Antagonists Sales Quantity by Region (2018-2029)
    • 9.3.2 Asia-Pacific Metabotropic Glutamate Antagonists Consumption Value by Region (2018-2029)
    • 9.3.3 China Market Size and Forecast (2018-2029)
    • 9.3.4 Japan Market Size and Forecast (2018-2029)
    • 9.3.5 Korea Market Size and Forecast (2018-2029)
    • 9.3.6 India Market Size and Forecast (2018-2029)
    • 9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
    • 9.3.8 Australia Market Size and Forecast (2018-2029)

10 South America

  • 10.1 South America Metabotropic Glutamate Antagonists Sales Quantity by Type (2018-2029)
  • 10.2 South America Metabotropic Glutamate Antagonists Sales Quantity by Application (2018-2029)
  • 10.3 South America Metabotropic Glutamate Antagonists Market Size by Country
    • 10.3.1 South America Metabotropic Glutamate Antagonists Sales Quantity by Country (2018-2029)
    • 10.3.2 South America Metabotropic Glutamate Antagonists Consumption Value by Country (2018-2029)
    • 10.3.3 Brazil Market Size and Forecast (2018-2029)
    • 10.3.4 Argentina Market Size and Forecast (2018-2029)

11 Middle East & Africa

  • 11.1 Middle East & Africa Metabotropic Glutamate Antagonists Sales Quantity by Type (2018-2029)
  • 11.2 Middle East & Africa Metabotropic Glutamate Antagonists Sales Quantity by Application (2018-2029)
  • 11.3 Middle East & Africa Metabotropic Glutamate Antagonists Market Size by Country
    • 11.3.1 Middle East & Africa Metabotropic Glutamate Antagonists Sales Quantity by Country (2018-2029)
    • 11.3.2 Middle East & Africa Metabotropic Glutamate Antagonists Consumption Value by Country (2018-2029)
    • 11.3.3 Turkey Market Size and Forecast (2018-2029)
    • 11.3.4 Egypt Market Size and Forecast (2018-2029)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
    • 11.3.6 South Africa Market Size and Forecast (2018-2029)

12 Market Dynamics

  • 12.1 Metabotropic Glutamate Antagonists Market Drivers
  • 12.2 Metabotropic Glutamate Antagonists Market Restraints
  • 12.3 Metabotropic Glutamate Antagonists Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry
  • 12.5 Influence of COVID-19 and Russia-Ukraine War
    • 12.5.1 Influence of COVID-19
    • 12.5.2 Influence of Russia-Ukraine War

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Metabotropic Glutamate Antagonists and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Metabotropic Glutamate Antagonists
  • 13.3 Metabotropic Glutamate Antagonists Production Process
  • 13.4 Metabotropic Glutamate Antagonists Industrial Chain

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Metabotropic Glutamate Antagonists Typical Distributors
  • 14.3 Metabotropic Glutamate Antagonists Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Metabotropic Glutamate Antagonists market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period.
    Metabotropic Glutamate Antagonists act by inhibiting the activity of glutamate receptors in the brain. These receptors are broadly divided into two major subtypes: N-methyl-D-aspartate (NMDA) and 3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors.
    The Global Info Research report includes an overview of the development of the Metabotropic Glutamate Antagonists industry chain, the market status of Hospitals And Clinics (Ionic, Non Ionic), Research Institutes (Ionic, Non Ionic), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Metabotropic Glutamate Antagonists.
    Regionally, the report analyzes the Metabotropic Glutamate Antagonists markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Metabotropic Glutamate Antagonists market, with robust domestic demand, supportive policies, and a strong manufacturing base.
    Key Features:
    The report presents comprehensive understanding of the Metabotropic Glutamate Antagonists market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Metabotropic Glutamate Antagonists industry.
    The report involves analyzing the market at a macro level:
    Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (K Units), revenue generated, and market share of different by Type (e.g., Ionic, Non Ionic).
    Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Metabotropic Glutamate Antagonists market.
    Regional Analysis: The report involves examining the Metabotropic Glutamate Antagonists market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
    Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Metabotropic Glutamate Antagonists market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
    The report also involves a more granular approach to Metabotropic Glutamate Antagonists:
    Company Analysis: Report covers individual Metabotropic Glutamate Antagonists manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
    Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Metabotropic Glutamate Antagonists This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hospitals And Clinics, Research Institutes).
    Technology Analysis: Report covers specific technologies relevant to Metabotropic Glutamate Antagonists. It assesses the current state, advancements, and potential future developments in Metabotropic Glutamate Antagonists areas.
    Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Metabotropic Glutamate Antagonists market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
    Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
    Market Segmentation
    Metabotropic Glutamate Antagonists market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
    Market segment by Type
    Ionic
    Non Ionic
    Market segment by Application
    Hospitals And Clinics
    Research Institutes
    Others
    Major players covered
    Artemis Neuroscience
    VistaGen Therapeutics
    Rottapharm Madaus
    Amorsa Therapeutics
    Newron Pharmaceuticals
    Purdue Biopharma
    Relmada Therapeutics
    BioCrea GmbH
    Cerecor Inc.
    NeurOp Inc.
    UCB SA
    Novartis AG
    Luc Therapeutics Inc.
    Evotec AG
    Market segment by region, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Metabotropic Glutamate Antagonists product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Metabotropic Glutamate Antagonists, with price, sales, revenue and global market share of Metabotropic Glutamate Antagonists from 2018 to 2023.
    Chapter 3, the Metabotropic Glutamate Antagonists competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Metabotropic Glutamate Antagonists breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
    Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Metabotropic Glutamate Antagonists market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
    Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Metabotropic Glutamate Antagonists.
    Chapter 14 and 15, to describe Metabotropic Glutamate Antagonists sales channel, distributors, customers, research findings and conclusion.

    Buy now